To explore the potential association between the dynamic changes in serum CTSF and FBLN1 concentrations and treatment response in NSCLC BM patients, we regularly collected serum samples of 35 patients in cohort 2 during their clinical follow-up. The gene discussed is FBLN1; the disease is non-small cell lung carcinoma.